- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04449718
Vitamin D Supplementation in Patients With COVID-19
16. november 2020 oppdatert av: ROSA MARIA RODRIGUES PEREIRA, University of Sao Paulo
Vitamin D Supplementation in Patients With COVID-19: A Randomized, Double-blind, Placebo-controlled Trial
Coronavirus disease 2019 (COVID-19) was declared an emergency public health problem by the World Health Organization (WHO) in March 2020.
Since then, several initiatives by the medical and scientific community have sought alternatives to treat infected individuals, as well as identifying risk or protective factors for the contamination and prognosis of patients.
In this perspective, vitamin D supplementation can improve some important outcomes in critically ill patients, being considered a potent immunomodulatory agent.
Vitamin D deficiency is a common outcome in critically ill patients, thus making it a modifiable risk factor with great potential for reducing hospital stay and intensive care and mortality.
The investigators speculate that vitamin D supplementation could have therapeutic effects in patients with COVID-19.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
240
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Sao Paulo, Brasil, 05403-000
- Clinical Hospital of the School of Medicine, University of Sao Paulo
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Diagnosis of flu syndrome with hospitalization criteria;
- Respiratory rate ≥ 24irpm and / or saturation <93% in room air, or belonging to the risk group for complications: 1. Chronic diseases: heart disease, diabetes mellitus, systemic arterial hypertension and neoplasms, 2. Immunosuppression, 3. Pulmonary tuberculosis; 4. Obesity;
- Tomographic findings compatible with coronavirus disease.
Exclusion Criteria:
- Patient admitted already under invasive mechanical ventilation;
- Patient admitted with severe acute respiratory syndrome and diagnosed with an etiologic agent other than SARS-CoV-2;
- Prior vitamin D supplementation (above 1000 IU/day);
- Renal failure requiring dialysis or creatinine ≥ 2.0mg/dl;
- Admitted patients with expected hospital discharge in less than 24 hours;
- Patient unable to sign the consent form.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Experimental
Patients will receive 200,000 IU of vitamin D3 on admission + conventional care
|
200,000 IU on admission
|
Placebo komparator: Placebo
Patients will receive an equivalent amount of a placebo solution on admission + conventional care
|
200,000 IU on admission
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Length of hospitalization
Tidsramme: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
total number of days that patient remained hospitalized
|
From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Mortality
Tidsramme: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
number of patients that died
|
From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
Number of cases admitted to Intensive Care Unit (ICU)
Tidsramme: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
total number of days that patient remained in ICU
|
From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
Length of use of mechanic ventilator
Tidsramme: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
total number of days that patient remained in mechanic ventilator
|
From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
Number and severity of symptoms
Tidsramme: From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
From date of randomization until the date of hospital discharge or death, which is usually less than 1 month
|
|
Inflammatory markers
Tidsramme: Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
C-reactive protein, IL-1alpha (pg/ml), IL-1beta (pg/ml), IL-6 (pg/ml), TNF-alpha (pg/ml), IL-1ra (pg/ml), IL-10 (pg/ml) concentration in the serum
|
Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
C-reactive protein
Tidsramme: Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
serum concentration
|
Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
Vitamin D
Tidsramme: Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
serum concentration
|
Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
Creatinine
Tidsramme: Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
serum concentration
|
Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
Calcium
Tidsramme: Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
serum concentration
|
Baseline, 14 days after hospitalization and at the moment of hospital discharge or death (usually less than 1 month)
|
Physical activity
Tidsramme: Baseline
|
Baecke questionnaire (higher scores mean a higher physical activity level)
|
Baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Rosa Pereira, PhD, MD, School of Medicine, University of Sao Paulo
- Studieleder: Bruno Gualano, PhD, School of Medicine, University of Sao Paulo
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Stroehlein JK, Wallqvist J, Iannizzi C, Mikolajewska A, Metzendorf MI, Benstoem C, Meybohm P, Becker M, Skoetz N, Stegemann M, Piechotta V. Vitamin D supplementation for the treatment of COVID-19: a living systematic review. Cochrane Database Syst Rev. 2021 May 24;5(5):CD015043. doi: 10.1002/14651858.CD015043.
- Fernandes AL, Sales LP, Santos MD, Caparbo VF, Murai IH, Pereira RMR. Persistent or new symptoms 1 year after a single high dose of vitamin D3 in patients with moderate to severe COVID-19. Front Nutr. 2022 Sep 13;9:979667. doi: 10.3389/fnut.2022.979667. eCollection 2022.
- Fernandes AL, Murai IH, Reis BZ, Sales LP, Santos MD, Pinto AJ, Goessler KF, Duran CSC, Silva CBR, Franco AS, Macedo MB, Dalmolin HHH, Baggio J, Balbi GGM, Antonangelo L, Caparbo VF, Gualano B, Pereira RMR. Effect of a single high dose of vitamin D3 on cytokines, chemokines, and growth factor in patients with moderate to severe COVID-19. Am J Clin Nutr. 2022 Mar 4;115(3):790-798. doi: 10.1093/ajcn/nqab426.
- Murai IH, Fernandes AL, Antonangelo L, Gualano B, Pereira RMR. Effect of a Single High-Dose Vitamin D3 on the Length of Hospital Stay of Severely 25-Hydroxyvitamin D-Deficient Patients with COVID-19. Clinics (Sao Paulo). 2021 Nov 26;76:e3549. doi: 10.6061/clinics/2021/e3549. eCollection 2021.
- Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KF, Duran CSC, Silva CBR, Franco AS, Macedo MB, Dalmolin HHH, Baggio J, Balbi GGM, Reis BZ, Antonangelo L, Caparbo VF, Gualano B, Pereira RMR. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021 Mar 16;325(11):1053-1060. doi: 10.1001/jama.2020.26848.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juni 2020
Primær fullføring (Faktiske)
7. oktober 2020
Studiet fullført (Faktiske)
7. oktober 2020
Datoer for studieregistrering
Først innsendt
16. juni 2020
Først innsendt som oppfylte QC-kriteriene
25. juni 2020
Først lagt ut (Faktiske)
29. juni 2020
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. november 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
16. november 2020
Sist bekreftet
1. juni 2020
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Luftveisinfeksjoner
- Sykdommer i luftveiene
- Lungebetennelse, viral
- Lungebetennelse
- Lungesykdommer
- Covid-19
- Fysiologiske effekter av legemidler
- Mikronæringsstoffer
- Vitaminer
- Bone Density Conservation Agents
- Vitamin d
Andre studie-ID-numre
- 30959620.4.0000.0068
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
Yang I. PachankisAktiv, ikke rekrutterendeCOVID-19 luftveisinfeksjon | COVID-19 stresssyndrom | Covid-19-vaksinebivirkning | COVID-19-assosiert tromboembolisme | COVID-19 Post-Intensive Care Syndrome | COVID-19-assosiert hjerneslagKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico og andre samarbeidspartnereFullførtPostakutte følgetilstander av COVID-19 | Tilstand etter covid-19 | Langvarig COVID | Kronisk COVID-19 syndromItalia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutteringCovid-19-pandemi | Covid-19-vaksiner | COVID-19 virussykdomIndonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkHar ikke rekruttert ennåPost-COVID-19 syndrom | Lang COVID | Lang Covid19 | Tilstand etter covid-19 | Post-COVID syndrom | Tilstand etter COVID-19, uspesifisert | Tilstand etter COVIDNederland
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyFullførtPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
Indonesia UniversityRekrutteringPost-COVID-19 syndrom | Lang COVID | Tilstand etter covid-19 | Post-COVID syndrom | Lang COVID-19Indonesia
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrutteringCOVID-19 lungebetennelse | COVID-19 luftveisinfeksjon | Covid-19-pandemi | COVID-19 akutt respiratorisk distress-syndrom | COVID-19-assosiert lungebetennelse | COVID 19 assosiert koagulopati | COVID-19 (Coronavirus Disease 2019) | COVID-19-assosiert tromboembolismeHellas
-
Endourage, LLCRekrutteringLang COVID | Lang Covid19 | Post-akutt COVID-19 | Langdistanse COVID | Langdistanse COVID-19 | Postakutt covid-19 syndromForente stater
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital og andre samarbeidspartnereRekrutteringKohortoppfølging av epidemi og nevroimaging for pasienter under den første bølgen av COVID-19 i KinaCovid-19 | Post-COVID-19 syndrom | Post-akutt COVID-19 | Akutt COVID-19Kina
Kliniske studier på Vitamin D
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens...FullførtVitamin D-mangelSlovenia
-
Khon Kaen UniversityHar ikke rekruttert ennå
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SAFullførtVitamin D-mangel | Overvekt og fedme | Overvektige ungdomColombia
-
USDA, Western Human Nutrition Research CenterFullført
-
University of ViennaUkjent
-
University Hospital, Basel, SwitzerlandFullført
-
University of AarhusHar ikke rekruttert ennåSykdommer i immunsystemet | Vekst | Barneutvikling | Vitamin D-tilskudd
-
Fundación Pública Andaluza para la gestión de la...FullførtHematopoetisk stamcelletransplantasjonSpania
-
Pauls Stradins Clinical University HospitalFullført
-
University of TromsoPublic Dental Service Competence Center of Northern NorwayHar ikke rekruttert ennåBetennelse | Periodontitt | Periodontale sykdommer | Vitamin d | Periodontal betennelse | Inflammasjon i tannkjøttetNorge